Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M23.1Revenue (TTM) $M5.6Net Margin (%)-349.0Altman Z-Score-37.7
Enterprise Value $M24.7EPS (TTM) $-6.0Operating Margin %-377.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-348.8Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.8Cash flow > EarningsY
Price/Sales1.45-y EBITDA Growth Rate %16.9Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-277.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.2ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NBY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-78.55view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-83.2view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-83.2view
Najafi RaminChairman 2015-03-03Buy6,667$15-83.2view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-84.49view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-85.18view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-84.73view
Najafi RaminChairman 2014-12-11Buy800$15-83.2view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-84.96view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-84.49view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
New Treatments for Contact Lens Intolerance On The Rise Jun 28 2016
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer Jun 13 2016
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer Jun 13 2016
NOVABAY PHARMACEUTICALS, INC. Financials May 27 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 27 2016
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results May 12 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 12 2016
NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results May 12 2016
NovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors May 09 2016
NovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors May 09 2016
NovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12 May 05 2016
NovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12 May 05 2016
NovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90% May 03 2016
Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface... May 03 2016
Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface... May 03 2016
[$$] NovaBay Not Seen Breaking Even for Years Apr 07 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K Mar 22 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)